Year Founded
2019
Ownership
Private
Employees
~10
Stage
Phase 1
Modalities
Small molecule

Miist Therapeutics General Information

Phase 1 results for MST01 showed 93% craving elimination within 2 minutes in smoking cessation. MST02 for migraine is in preclinical development.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Alameda, California
United States

Drug Pipeline

MST01
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Miist Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Miist Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Miist Therapeutics's complete valuation and funding history, request access »

Miist Therapeutics Investors

Refactor Capital
Investor Type: Venture Capital
Holding: Minority
1517 Fund
Investor Type: Venture Capital
Holding: Minority
Freeflow Ventures
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 5 investors. Get the full list »